Axcynsis Therapeutics
Clinical-stage Singapore company developing Antibody-X Conjugates (AXCs); founded in February 2022 as Tetris Therapeutics and renamed in July 2022, it applies its proprietary AxcynDOT and DuXd payload platforms across first- and best-in-class programs including AT-01 (ROR1 dual payload), AT-03 (CLDN6), AT-00 (HER2) and the bispecific ADC AT-06 (DLL3 x SEZ6).
Headquarters
Singapore
Year Founded
2022
Founders
Zou Bin (founder and CEO)
Country
Singapore
Financial Information
Funding Stage
Seed
Recent Funding
$15M
Funding By
Trinity Innovation Bioventure Singapore (TIBS)
Core Technology
Antibody-X Conjugate platform with AxcynDOT and DuXd payloads
Product Type
Drug
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Not disclosed
- FDA/EMA Status: Not disclosed
- Clinical Trial Registration: Not disclosed
- Patents / IP Status: Proprietary AxcynDOT and DuXd payload platforms
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
Not disclosed
Market & Differentiation
Dual-payload and bispecific conjugate designs aimed at low-expression targets and acquired resistance